Immunocore Holdings plc

IMCR Nasdaq SEC CIK 1671927
Follow Immunocore Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $102.2M −1.4% vs same quarter last year
Net income −$14.2M −7935% vs same quarter last year
EPS, diluted −$0.28
Operating cash flow $20.1M +550.9% vs same quarter last year
Revenue by quarter
$84.1M
$93.9M
$98M
$103.7M
$104.5M
$106.7M
$115.9M
$102.2M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income6 fiscal years
  • Revenue
  • Net income
−$200M$0$200M$400M$600MFY20FY21FY22FY23FY24FY25
Show the numbers
YearRevenueNet income
FY25$400M−$35.5M
FY24$310.2M−$51.1M
FY23$249.4M−$55.3M
FY22$174.4M−$52.5M
FY21$4.1M−$180M
FY20--
MarginsShare of revenue
  • Gross margin
  • Operating margin
  • Net margin
−6000%−4000%−2000%0%2000%FY20FY21FY22FY23FY24FY25
Show the numbers
YearGross marginOperating marginNet margin
FY2598.7%−11.3%−8.9%
FY2499.1%−22.7%−16.5%
FY2399.6%−23.9%−22.2%
FY2299.4%−29.7%−30.1%
FY21100%−4281.2%−4414.6%
FY20---
Free cash flowOperating cash flow minus capital expenditure
−$150M−$100M−$50M$0$50MFY20FY21FY22FY23FY24FY25
Show the numbers
YearFree cash flow
FY25−$15.1M
FY24$20.9M
FY23−$2.5M
FY22−$51.4M
FY21−$144.5M
FY20-
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Immunocore
  • Healthcare median
−6000%−4000%−2000%0%FY20FY21FY22FY23FY24FY25
Show the numbers
YearImmunocoreHealthcare median
FY25−8.9%−30.6%
FY24−16.5%−47%
FY23−22.2%−58%
FY22−30.1%−80.4%
FY21−4414.6%−71.9%
FY20-−62.2%